Anti-CD28 x Anti-CD3 Bispecific Antibody (IgG-IgG) (BSIG-054)

Anti-CD28 x Anti-CD3 Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD28 and anti-CD3 parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can improve T-cell activation. It is designed for the research of Tumors therapy.

Datasheet

Specifications

Targets

CD28 & CD3

Type

IgG-IgG

Species Reactivity

Human

Target 1

CD28

Host Animal 1

Mouse

Target 2

CD3

Host Animal 2

Mouse

Application

FuncS; Promising therapeutic agent

Related Disease

Tumors

Targets

Target 1

CD28

Gene ID

940

UniProt ID

P10747

Alternative Names

CD28; CD28 molecule; Cluster of Differentiation 28; Tp44; T-cell-specific surface glycoprotein CD28; CD28 antigen

Target 2

CD3

Gene ID

916

UniProt ID

P07766

Alternative Names

CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Welcome! For price inquiries, we will get back to you as soon as possible.

To order, please email

INQUIRY

Online Inquiry

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:

UK
167-169 Great Portland Street, 5th Floor, London, W1W 5PE
Tel: 44-207-097-1828
Email: